These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30048801)

  • 1. High potency of lipid conjugated TLR7 agonist requires nanoparticulate or liposomal formulation.
    Gadd AJR; Castelletto V; Kabova E; Shankland K; Perrie Y; Hamley I; Cobb AJA; Greco F; Edwards AD
    Eur J Pharm Sci; 2018 Oct; 123():268-276. PubMed ID: 30048801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01.
    Wilkinson A; Lattmann E; Roces CB; Pedersen GK; Christensen D; Perrie Y
    J Control Release; 2018 Dec; 291():1-10. PubMed ID: 30291987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and immunostimulatory activity of sugar-conjugated TLR7 ligands.
    Baba A; Wakao M; Shinchi H; Chan M; Hayashi T; Yao S; Cottam HB; Carson DA; Suda Y
    Bioorg Med Chem Lett; 2020 Feb; 30(3):126840. PubMed ID: 31864800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The adjuvant effect of TLR7 agonist conjugated to a meningococcal serogroup C glycoconjugate vaccine.
    Donadei A; Balocchi C; Mancini F; Proietti D; Gallorini S; O'Hagan DT; D'Oro U; Berti F; Baudner BC; Adamo R
    Eur J Pharm Biopharm; 2016 Oct; 107():110-9. PubMed ID: 27388628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UC-1V150, a potent TLR7 agonist capable of activating macrophages and potentiating mAb-mediated target cell deletion.
    Dahal LN; Gadd A; Edwards AD; Cragg MS; Beers SA
    Scand J Immunol; 2018 Jun; 87(6):e12666. PubMed ID: 29667229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of the Immunostimulatory Activity of a TLR7 Ligand by Conjugation to Polysaccharides.
    Shinchi H; Crain B; Yao S; Chan M; Zhang SS; Ahmadiiveli A; Suda Y; Hayashi T; Cottam HB; Carson DA
    Bioconjug Chem; 2015 Aug; 26(8):1713-23. PubMed ID: 26193334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conjugation of a TLR7 agonist and antigen enhances protection in the S. pneumoniae murine infection model.
    Vecchi S; Bufali S; Uno T; Wu T; Arcidiacono L; Filippini S; Rigat F; O'Hagan D
    Eur J Pharm Biopharm; 2014 Jul; 87(2):310-7. PubMed ID: 24434202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted Activation of Toll-Like Receptors: Conjugation of a Toll-Like Receptor 7 Agonist to a Monoclonal Antibody Maintains Antigen Binding and Specificity.
    Gadd AJ; Greco F; Cobb AJ; Edwards AD
    Bioconjug Chem; 2015 Aug; 26(8):1743-52. PubMed ID: 26133029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The preparation and characterization of PLG nanoparticles with an entrapped synthetic TLR7 agonist and their preclinical evaluation as adjuvant for an adsorbed DTaP vaccine.
    Bruno C; Agnolon V; Berti F; Bufali S; O'Hagan DT; Baudner BC
    Eur J Pharm Biopharm; 2016 Aug; 105():1-8. PubMed ID: 27224856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conjugation of a Small-Molecule TLR7 Agonist to Silica Nanoshells Enhances Adjuvant Activity.
    Huang CH; Mendez N; Echeagaray OH; Weeks J; Wang J; Vallez CN; Gude N; Trogler WC; Carson DA; Hayashi T; Kummel AC
    ACS Appl Mater Interfaces; 2019 Jul; 11(30):26637-26647. PubMed ID: 31276378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyaluronic Acid Conjugates of TLR7/8 Agonists for Targeted Delivery to Secondary Lymphoid Tissue.
    Yoo E; Salyer ACD; Brush MJH; Li Y; Trautman KL; Shukla NM; De Beuckelaer A; Lienenklaus S; Deswarte K; Lambrecht BN; De Geest BG; David SA
    Bioconjug Chem; 2018 Aug; 29(8):2741-2754. PubMed ID: 29969553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of a TLR7 agonist to an acellular pertussis vaccine enhances Th1 and Th17 responses and protective immunity in a mouse model.
    Misiak A; Leuzzi R; Allen AC; Galletti B; Baudner BC; D'Oro U; O'Hagan DT; Pizza M; Seubert A; Mills KHG
    Vaccine; 2017 Sep; 35(39):5256-5263. PubMed ID: 28823618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses.
    Davidsen J; Rosenkrands I; Christensen D; Vangala A; Kirby D; Perrie Y; Agger EM; Andersen P
    Biochim Biophys Acta; 2005 Dec; 1718(1-2):22-31. PubMed ID: 16321607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists.
    Hamm S; Rath S; Michel S; Baumgartner R
    J Immunotoxicol; 2009 Dec; 6(4):257-65. PubMed ID: 19848448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of incorporating cholesterol into DDA:TDB liposomal adjuvants on bilayer properties, biodistribution, and immune responses.
    Kaur R; Henriksen-Lacey M; Wilkhu J; Devitt A; Christensen D; Perrie Y
    Mol Pharm; 2014 Jan; 11(1):197-207. PubMed ID: 24171445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and immunostimulatory activity of substituted TLR7 agonists.
    Akinbobuyi B; Wang L; Upchurch KC; Byrd MR; Chang CA; Quintana JM; Petersen RE; Seifert ZJ; Boquin JR; Oh S; Kane RR
    Bioorg Med Chem Lett; 2016 Sep; 26(17):4246-9. PubMed ID: 27476423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegylation of DDA:TDB liposomal adjuvants reduces the vaccine depot effect and alters the Th1/Th2 immune responses.
    Kaur R; Bramwell VW; Kirby DJ; Perrie Y
    J Control Release; 2012 Feb; 158(1):72-7. PubMed ID: 22032883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A conjugate of octamer-binding transcription factor 4 and toll-like receptor 7 agonist prevents the growth and metastasis of testis embryonic carcinoma.
    Lin G; Wang X; Yi W; Zhang C; Xu G; Zhu X; Cai Z; Liu Y; Diao Y; Lin MC; Jin G
    J Transl Med; 2015 May; 13():166. PubMed ID: 25990580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Preparation and Physicochemical Characterization of Aluminum Hydroxide/TLR7a, a Novel Vaccine Adjuvant Comprising a Small Molecule Adsorbed to Aluminum Hydroxide.
    Malyala P; Laera D; Cianetti S; Bufali S; Aggravi M; Ianni E; Judge C; Otten G; Singh M; O'Hagan DT
    J Pharm Sci; 2018 Jun; 107(6):1577-1585. PubMed ID: 29421216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the adjuvant effect of agonists of toll-like receptor 4 and 7/8 in a vaccine against leishmaniasis in BALB/c mice.
    Rostamian M; Niknam HM
    Mol Immunol; 2017 Nov; 91():202-208. PubMed ID: 28963929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.